(Q51906755)

17 April 2018

title

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. (English)

1 reference

17 April 2018

1 reference

15

1 reference

17 April 2018

Anne W Ekdahl

object named as

Anne Ekdahl

6

0 references

Lennart Minthon

16

object named as

Lennart Minthon

1 reference

17 April 2018

Asa K Wallin

1

1 reference

17 April 2018

Niels Andreasen

2

1 reference

17 April 2018

Sture Eriksson

3

1 reference

17 April 2018

Stellan Båtsman

4

1 reference

17 April 2018

Birgitta Nasman

5

1 reference

17 April 2018

Lena Kilander

7

1 reference

17 April 2018

Mikaela Grut

8

1 reference

17 April 2018

Marie Rydén

9

1 reference

17 April 2018

Anders Wallin

10

1 reference

17 April 2018

Mikael Jonsson

11

1 reference

17 April 2018

Hasse Olofsson

12

1 reference

17 April 2018

Elisabeth Londos

13

1 reference

17 April 2018

Carina Wattmo

14

1 reference

17 April 2018

Swedish Alzheimer Treatment Study Group

17

1 reference

17 April 2018

publication date

18 December 2006

1 reference

17 April 2018

Dementia and Geriatric Cognitive Disorders

published in

1 reference

17 April 2018

volume

23

1 reference

17 April 2018

issue

3

1 reference

17 April 2018

page(s)

150-160

1 reference

17 April 2018

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years

cites work

1 reference

Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups

21 January 2018

1 reference

The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease

21 January 2018

1 reference

A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

21 January 2018

1 reference

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis

21 January 2018

1 reference

Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations

21 January 2018

1 reference

Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease

21 January 2018

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

21 January 2018

1 reference

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.

21 January 2018

1 reference

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration

21 January 2018

1 reference

Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations

21 January 2018

1 reference

Modelling mini mental state examination changes in Alzheimer's disease

21 January 2018

1 reference

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

21 January 2018

1 reference

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

21 January 2018

1 reference

Rivastigmine in Alzheimer disease: efficacy over two years

21 January 2018

1 reference

Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial

21 January 2018

1 reference

The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial

21 January 2018

1 reference

Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years

21 January 2018

1 reference

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

21 January 2018

1 reference

Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

21 January 2018

1 reference

Disease stage in Alzheimer disease and treatment effects of rivastigmine

21 January 2018

1 reference

Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.

21 January 2018

1 reference

Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease

21 January 2018

1 reference

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

21 January 2018

1 reference

Donepezil in the treatment of patients with Alzheimer's disease

21 January 2018

1 reference

Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000098052

1 reference

17 April 2018

1 reference

17 April 2018